Recursion is rare among biotechs because it's developing medicines in-house while banking on big AI collaborations and licensing revenue from its platform to stay afloat in the meantime. By mid-2026, ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Researchers at the University of Tübingen have found via experimentation that crows are capable of understanding the concept of recursion. In their paper published in the journal Science Advances, ...
AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results